Annual report [Section 13 and 15(d), not S-K Item 405]

Revenue Recognition (Tables)

v3.25.0.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Service Line

Revenue by Service Line

 

 

Years Ended December 31,

 

(in thousands)

 

2024

 

 

2023

 

Biologics and drug delivery

 

 

 

 

 

 

Disposable products

 

$

5,606

 

 

$

2,154

 

Services and license fees

 

 

11,704

 

 

 

11,448

 

Subtotal – Biologics and drug delivery revenue

 

 

17,310

 

 

 

13,602

 

Neurosurgery navigation and therapy

 

 

 

 

 

 

Disposable products

 

 

10,285

 

 

 

7,589

 

Services

 

 

 

 

 

931

 

Subtotal – Neurosurgery navigation and therapy revenue

 

 

10,285

 

 

 

8,520

 

Capital equipment and software

 

 

 

 

 

 

Systems and software products

 

 

2,735

 

 

 

860

 

Services

 

 

1,060

 

 

 

973

 

Subtotal – Capital equipment and software revenue

 

 

3,795

 

 

 

1,833

 

Total revenue

 

$

31,390

 

 

$

23,955

 

Schedule of Other Current Assets

 

(in thousands)

 

December 31, 2024

 

 

December 31, 2023

 

 

December 31, 2022

 

Accounts receivable, net

 

$

4,713

 

 

$

3,211

 

 

$

2,665

 

Other contract assets

 

 

 

 

 

 

 

 

 

Unbilled receivables

 

$

642

 

 

$

733

 

 

$

43

 

Deferred contract costs

 

$

 

 

$

 

 

$

327

 

Schedule of Revenue Recognized by Contract Liability

(in thousands)

 

December 31, 2024

 

 

December 31, 2023

 

 

December 31, 2022

 

Deferred revenues

 

$

2,557

 

 

$

3,154

 

 

$

1,457

 

Refund liability

 

$

 

 

$

 

 

$

500